Introduction: Infusing high-density lipoprotein (HDL) has been shown to promote plaque regression in patients with acute coronary syndrome (ACS). The factors associated with a greater propensity to regression have not been elucidated.\n\nWe hypothesized greater plaque regression with HDL infusion would be observed in patients with greater baseline plaque burden.\n\nMethods: The CHI-SQUARE study compared the effect of infusing the pre-beta HDL mimetic CER-001 (3 to 12 mg/kg) versus placebo weekly for 5 weeks in patients with a recent ACS on plaque burden using serial intravascular ultrasound. Receiver operating characteristics curve analysis determined that a baseline percent atheroma volume (PAV) ≥30% optimally associated with greater regression. Clinical and imaging characteristics were compared in patients with baseline PAV !\n\n : /embed/graphic-1.gif
|Issue number||Suppl 3|
|Publication status||Published - 2015|
Kataoka, Y., Andrews, J., Duong, M., Nguyen, T., Schwarz, N., Fendler, J., ... Nicholls, S. J. (2015). Abstract 12156: Greater Regression of Coronary Atherosclerosis With the Pre-Beta High-Density Lipoprotein Mimetic CER-001 in Patients With More Extensive Plaque Burden. Circulation, 132(Suppl 3), A12156-A12156.